The latest (2020) NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Version 3.2020 also recommend germline genetic testing for men with NCCN high-risk, very high risk regional or metastatic PrCa, for all men of Ashkenazi Jewish ancestry, a known FH of BRCA1/2 or Lynch Syndrome, a FH of brother/father/multiple family members diagnosed with PrCa (except GGG1) at < 60 years old OR who died from PrCa. The gene discussed is BRCA1; the disease is prostate carcinoma.